公开(公告)号：US20240293531A1

公开(公告)日：2024-09-05

申请号：US17913638

申请日：2021-04-06

申请人： Valneva Austria GmbH

发明人： Andreas Meinke ,  Michael Möhlen ,  Robert Schlegl ,  Jürgen Heindl-Wruss

IPC分类号： A61K39/215 ,  A61K39/00 ,  A61P31/14 ,  C12N7/00

CPC分类号： A61K39/215 ,  A61P31/14 ,  C12N7/00 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/575 ,  C12N2770/20034 ,  C12N2770/20063

摘要： Described herein are SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

公开(公告)号：US11684669B2

公开(公告)日：2023-06-27

申请号：US17471904

申请日：2021-09-10

申请人： Valneva Austria GmbH ,  Dynavax Technologies Corporation

发明人： Andreas Meinke ,  Michael Möhlen ,  Christoph Reinisch ,  Robert Schlegl ,  Christian Taucher ,  John Campbell ,  David Novack ,  Robert S. Janssen ,  Jürgen Heindl-Wruss

IPC分类号： C12N7/00 ,  A61K39/215 ,  A61K39/00

CPC分类号： A61K39/215 ,  A61K2039/545 ,  A61K2039/55561

摘要： Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

公开(公告)号：US09913898B2

公开(公告)日：2018-03-13

申请号：US15223027

申请日：2016-07-29

申请人： Valneva Austria GmbH

发明人： Robert Schlegl ,  Michael Möhlen ,  Jürgen Wruss ,  Michael Weber

IPC分类号： A61K39/00 ,  A61K39/39 ,  C07D487/04 ,  C09K13/00 ,  A61K38/43 ,  A61K38/16 ,  A61K39/12 ,  C12N7/00 ,  A61K39/104

CPC分类号： A61K39/39 ,  A61K38/162 ,  A61K38/164 ,  A61K39/104 ,  A61K39/12 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N7/00 ,  C12N2770/24134 ,  Y02A50/39

摘要： The invention relates to means and methods for preparing aqueous composition comprising aluminum and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminum content. The invention further relates to aqueous compositions comprising a protein and an aluminum-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.

公开(公告)号：US20150216967A1

公开(公告)日：2015-08-06

申请号：US14258119

申请日：2014-04-22

申请人： Valneva Austria GmbH

发明人： Benjamin Wizel ,  Karin Riedl ,  Karen Lingnau ,  Ursula Schlosser ,  Jürgen Wruss ,  Robert Schlegl ,  Michael Weber ,  Christoph Reinisch ,  Ljubomir Paucz ,  Christoph Klade ,  Jee Loon Look ,  Christian Ruiz ,  Robert Seid

IPC分类号： A61K39/39 ,  C12N7/00 ,  A61K39/09 ,  A61K39/145 ,  A61K9/14 ,  A61K39/118

CPC分类号： A61K39/39 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/10 ,  A61K9/14 ,  A61K9/51 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/092 ,  A61K39/118 ,  A61K39/12 ,  A61K39/145 ,  A61K39/40 ,  A61K39/42 ,  A61K48/00 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/70 ,  C12N7/00 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2760/16234 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/396 ,  Y02A50/401 ,  Y02A50/412 ,  Y02A50/47

摘要： The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 μm.

摘要翻译： 本发明公开了液体形式的药物组合物，其包含具有氨基酸序列KLKL5KLK的肽和具有核酸序列（dIdC）13的寡脱氧核苷酸的肽，并且其中肽和寡脱氧核苷酸作为无菌可过滤纳米粒子存在于组合物中，由此形成 悬浮液，其特征在于固体颗粒的平均粒径小于1μm。

公开(公告)号：US20230398210A1

公开(公告)日：2023-12-14

申请号：US17917010

申请日：2021-04-09

申请人： Valneva Austria GmbH

发明人： Robert Schlegl ,  Jürgen Heindl-Wruss

IPC分类号： A61K39/39 ,  A61K47/20 ,  A61K39/02 ,  A61K47/02

CPC分类号： A61K39/39 ,  A61K47/20 ,  A61K39/0225 ,  A61K47/02 ,  A61K2039/55505

摘要： The present invention relates to an aluminum composition for use as an adjuvant or for use in a method of vaccination, the use of an alum-adjuvanted vaccine composition comprising less than 1.25 ppb copper for increasing bioavailability of an antigen in the vaccine, wherein the antigen is a protein, particularly an OspA protein or a Clostridium difficile toxin A and toxin B fusion protein or a SARS-CoV-2 protein or an hMPV protein, in an aluminum-containing vaccine composition and the use of a radical quenching compound such as L-methionine for increasing bioavailability of a protein antigen in a copper- and aluminum-containing vaccine composition.

公开(公告)号：US20230295245A1

公开(公告)日：2023-09-21

申请号：US17932226

申请日：2022-09-14

申请人： Valneva Austria GmbH

发明人： Pär Comstedt ,  Urban Lundberg ,  Andreas Meinke ,  Markus Hanner ,  Wolfgang Schüler ,  Benjamin Wizel ,  Christoph Reinisch ,  Brigitte Grohmann ,  Robert Schlegl

IPC分类号： C07K14/20 ,  C07K16/12 ,  C12P21/02 ,  A61K39/02 ,  C12N5/07 ,  C12N15/70 ,  C12P21/00

CPC分类号： C07K14/20 ,  C07K16/12 ,  C12P21/02 ,  A61K39/0225 ,  A61K39/02 ,  C12N5/06 ,  C12N15/70 ,  C07K16/1207 ,  C12P21/00 ,  A61K2039/55505

摘要： The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.

公开(公告)号：US11110170B2

公开(公告)日：2021-09-07

申请号：US16734866

申请日：2020-01-06

申请人： Valneva Austria GmbH

发明人： Robert Schlegl ,  Michael Möhlen ,  Jürgen Heindl-Wruss ,  Michael Weber

IPC分类号： A61K39/395 ,  A61K39/39 ,  A61K38/16 ,  A61K39/12 ,  C12N7/00 ,  A61K39/104 ,  A61K39/00

摘要： The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.

公开(公告)号：US10668146B2

公开(公告)日：2020-06-02

申请号：US15469689

申请日：2017-03-27

申请人： Valneva Austria GmbH

发明人： Robert Schlegl ,  Michael Möhlen ,  Jürgen Heindl-Wruss ,  Michael Weber

IPC分类号： A61K39/395 ,  A61K39/39 ,  A61K38/16 ,  A61K39/104 ,  A61K39/12 ,  C12N7/00 ,  A61K39/00

摘要： The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.

公开(公告)号：US09884115B2

公开(公告)日：2018-02-06

申请号：US14873344

申请日：2015-10-02

申请人： Valneva Austria GmbH

发明人： Robert Schlegl ,  Michael Möhlen ,  Jürgen Wruss ,  Michael Weber

IPC分类号： A61K39/00 ,  A61K39/39 ,  C07D487/04 ,  C09K13/00 ,  H01L21/02 ,  A61K38/16 ,  A61K39/12 ,  C12N7/00 ,  A61K39/104

CPC分类号： A61K39/39 ,  A61K38/162 ,  A61K38/164 ,  A61K39/104 ,  A61K39/12 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N7/00 ,  C12N2770/24134 ,  Y02A50/39

摘要： The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.

公开(公告)号：US20170101446A1

公开(公告)日：2017-04-13

申请号：US15272581

申请日：2016-09-22

申请人： Valneva Austria GmbH

发明人： Pär Comstedt ,  Urban Lundberg ,  Andreas Meinke ,  Markus Hanner ,  Wolfgang Schüler ,  Benjamin Wizel ,  Christoph Reinisch ,  Brigitte Grohmann ,  Robert Schlegl

IPC分类号： C07K14/20 ,  A61K39/02

摘要： The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.